Randomized, double-blind, phase II study of tiragolumab plus atezolizumab versus placebo plus atezolizumab as first-line treatment for PD-L1-selected NSCLC (CITYSCAPE)

Rodriguez-Abreu, Delvys; ...; Secen, Nevena M; ...; (broj, koautora 21)

Rezultati

eNauka > Results > Randomized, double-blind, phase II study of tiragolumab plus atezolizumab versus placebo plus atezolizumab as first-line treatment for PD-L1-selected NSCLC (CITYSCAPE)

Title:	Randomized, double-blind, phase II study of tiragolumab plus atezolizumab versus placebo plus atezolizumab as first-line treatment for PD-L1-selected NSCLC (CITYSCAPE)
Authors:	Rodriguez-Abreu, Delvys; ...; Secen, Nevena M; ...; (broj, koautora 21)
Issue Date:	2020
Publication:	SWISS MEDICAL WEEKLY
ISSN:	1424-7860 Swiss Medical Weekly Search Idenfier
Type:	Conference Paper
Collation:	str. 31S-31S
WoS-ID:	000592781900075
URI:	https://enauka.gov.rs/handle/123456789/813302
Metadata source:	(Preuzeto iz Nasi u WoS)
M-category:	Mp. category will be shown later

Pronađi DOI

Pronalaženje DOI u servisu CrossRef-u na osnovu meta-podataka u zapisu. Prikazaće se DOI (i metapodaci) čiji se podaci najviše poklapaju. OPREZ - to ne mora biti ta publikacija.

Google Scholar^TM

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.